The first global consensus on inflammatory bowel disease and pregnancy delivers clinician-focused, evidence-based guidance ...
Pharmaceutical Technology on MSN
McMaster University and MIT discover new antibiotic for IBD
Discovered at McMaster, the newly identified antibiotic presents a potential new therapy for individuals living with Crohn's ...
Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their anti-TL1A antibody duvakitug into a phase 3 programme in inflammatory bowel disease (IBD). The results of the ...
Subcutaneous vedolizumab dose intensification restored steroid-free clinical response in approximately one-third of patients with IBD.
Department of Chemistry and Institute for Bimolecular Design and Discovery (IBD), Carnegie Mellon University, 4400 Fifth Avenue, Pittsburgh, Pennsylvania 15213, United States ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback